Xoma traded at $25.56 this Friday February 27th, decreasing $1.20 or 4.48 percent since the previous trading session. Looking back, over the last four weeks, Xoma lost 3.65 percent. Over the last 12 months, its price rose by 12.60 percent. Looking ahead, we forecast Xoma to be priced at 25.01 by the end of this quarter and at 22.76 in one year, according to Trading Economics global macro models projections and analysts expectations.
XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that is licensed to pharmaceutical or biotechnology companies. Its product candidates include PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, an insulin receptor-activating antibody, and X213, an allosteric inhibitor of prolactin action. It has a range of antibody discovery and development technologies, which includes antibody discovery advanced platform technologies (ADAPT), ModulX and OptimX. The ADAPT technology includes phage display libraries integrated with yeast and mammalian display. Its ModulX technology enables the identification of allosteric antibodies for positive or negative modulation of biological pathways. The OptimX technology is used for optimizing biophysical properties of antibodies.